2023 ACMG Annual Clinical Genetics Meeting Digital Edition: Poster Gallery-ELEVATED LEVELS OF CXCL16 IN SEVERE COVID-19 PATIENTS: EFFECTS ON MORTALITY

Pdf Summary

The study conducted by C.E. Johnson et al. aimed to assess the plasma concentrations of CXCL16 in severe COVID-19 patients and its effects on mortality. The researchers collected plasma samples from two clinical studies, ODYSSEY and CALYPSO, and measured CXCL16 levels using ELISA. They also conducted whole genome sequencing on all samples.<br /><br />The findings revealed that elevated levels of CXCL16 were observed in the plasma of COVID-19 patients, and this elevation was associated with increased mortality. This effect was consistent in both the ODYSSEY and CALYPSO cohorts, indicating the reproducibility of the findings. Further analysis showed that at a CXCL16 level of 700 pg/mL, the likelihood of mortality was significantly increased.<br /><br />The study also explored the role of the CXCR6/CXCL16 axis in the immunopathogenesis of severe COVID-19. This axis is involved in the homing of T cells to the lungs and is associated with cellular injury. The researchers noted preliminary data suggesting decreased expression of CXCR6 in severe patients.<br /><br />The study concludes that elevated levels of CXCL16 are significantly associated with increased mortality in severe COVID-19 patients. These findings highlight the potential importance of the CXCR6/CXCL16 axis in the pathogenesis of the disease. The researchers recommend further studies to understand which patients would benefit the most from targeted treatments.<br /><br />Overall, this study provides valuable insights into the role of CXCL16 in severe COVID-19 and its impact on mortality. The findings contribute to our understanding of the immunopathogenesis of the disease and have implications for potential therapeutic interventions.

Asset Subtitle

Presenting Author - Sanda Smieszek, PhD;

Meta Tag

Clinical History

Delineation of Diseases

Disruption

Presenting Author Sanda Smieszek, PhD

Keywords

CXCL16

plasma concentrations

severe COVID-19 patients

mortality

ODYSSEY

CALYPSO

ELISA

whole genome sequencing

CXCR6/CXCL16 axis

immunopathogenesis